Lacosamide

CAS 175481-36-4 31 API suppliersSmall Molecule

Overview

Lacosamide is an antiepileptic drug used primarily to treat partial-onset seizures. It works by selectively enhancing slow inactivation of voltage-gated sodium channels, thereby stabilizing hyperexcitable neuronal membranes.

API suppliers (31)

Suppliers of Lacosamide evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
India21China2Netherlands1Italy1Pakistan1

Country recorded for 26 of 31 suppliers.

16 of 31 hold a GMP certificate on record in the EU or UK registers

Showing 25 of 31 suppliers — see the full list in the app.

Patent & exclusivity (US)

Per the FDA Orange Book (82 approved US products), the latest listed US patent on Lacosamide expires 5 Jun 2040 and exclusivity 28 Apr 2026. Generic API sourcing typically opens up once these lapse.

Therapeutic areas

NeurologyEpilepsySeizure Disorders
Verified Supplier Partner

Do you supply Lacosamide? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.